The Norwegian plasma fractionation project - A 12 year clinical and economic success story

Transfusion and Apheresis Science

Volumn 28, Issue 1, 2003, Pages 93-100

  Flesland, O ^a,b   Seghatchian, J ^c   Solheim, B G ^b  

^a VESTRE VIKEN HOSPITAL TRUST   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c Blood Component Technol H   (United Kingdom)

Author keywords

Blood; Factor VIII; HAV: hepatitis A virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; IVIgG; Octaplas ; Plasma; Plasma fractionation; SD plasma; SD: solvent detergent; Self sufficiency; Uniplas

Indexed keywords

BLOOD CLOTTING FACTOR 9; IMMUNOGLOBULIN G; PLASMA PROTEIN;

BLOOD BANK; CRYOPRECIPITATE; ECONOMIC ASPECT; FRACTIONATION; HUMAN; MARKET; NORWAY; ORGANIZATION; PLASMA; RESEARCH; REVIEW; VIRUS INACTIVATION;

EID: 0037293170     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-0502(02)00104-0     Document Type: Review

References (24)

1. Evensen S.A., Ulstrup J., Skaug K., Fröland S.S., Glomstein A., Rollag H. HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in heamophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur. J. Haematol. 39:1887;44-48.
2. Solheim B.G., Heier H.E., Evensen S.A. Self-sufficiency for blood and plasma products in Norway. Biol. Clin. Heamtol. 14:1992;103-105.
3. Retningslinjer for GMP i blodbanker. Statens helsetilsyns veiledningsserie 1-1996. Oslo: Statens helsetilsyn; 1996.
4. Nordoy I., Schrumpf E., Elgjo K., Flesland O., Andersen Glende J., Orjasaeter H. et al. Liver disease in anti-hepatitis C virus-positive Norwegian blood donors. Scand. J. Gastroenterol. 29:1994;77-81.
5. Aukrust P., Muller F., Svenson M., Nordoy I., Bendtzen K., Fronland S.S. Administration of intravenous immonolobulin (IVIG) in vivo - down-reguolatory effects on the IL-1 system. Clin. Exp. Immunol. 115:1999;136-143.
6. Gullestad L., Aass H., Fjeld J.G., Wikeby L., Andreassen A.K., Ihlen H. et al. Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 103:2001;220-225.
7. Aukrust P., Gullestad L., Lappegard K.T., Ueland T., Aass H., Wikeby L. et al. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunolglobulin treatment. Circulation. 104:2001;1494-1500.
8. Solheim B.G., Svennevig J.L., Mohr B., Dragsund M., Noddeland H., Töllöfsrud S. et al. The use of Octaplas in patients undergoing open heart surgery. Müller-Berghaus G., Madlener K., Blombäck M., Ten Cate J.W. DIC Pathogenesis and Disseminated Intravascular Fibrin Formation. 1993;253-262 Excerpta Medica, Elsevier Science Publishers, Amsterdam.
9. Solheim B.G., Eggen B.M., Heier H.E. Self-sufficiency for plasma and plasma proteins in Norway. Sibrowski W., Stangel W., Blauhut B. Transfusionsmedizin 1995/96. vol. 33:1966;98-102 Beitr Infusionsther Transfusionsmed.
10. Solheim B.G., Rollag H., Svennevig J.L., Arafa O., Fosse E., Bergerud U. Viral safety of solvent/detergent treated plasma. Transfusion. 40:2000;84-90.
11. ® ) rationale and clinical properties Thromb Res. 107:2002;533-537.
12. ® ) - a safe product in open heart surgery, submitted for publication.
13. Rollag H., Solheim B.G., Svennevig J.L. Viral safety of blood derivatives by immune neutralization. Vox Sang. 74(Suppl 1):1998;213-221.
14. Nordbo A, Andersen A, Kongsgaard UE, Bormer OP, Olsen H. Pharmaceutical-grade albumin: impared drug-binding capacity in vitro, in preparation.
15. Haubelt H., Blome M., Kiessling A.H. et al. Effects of solvent/detergent-treated plasma and fresh-forzen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang. 82:2002;9-14.
16. Mast A.E., Stadanlick J.E., Lockett J.M., Dietzen D.J. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood. 94:1999;3922-3927.
17. Hellstern P., Sachse H., Schwinn H., Oberfrank K. Manufacture and in vitro characterization of solvent/detergent-treated human plasma. Vox Sang. 63:1992;178-185.
18. Beeck H., Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 74(Suppl 1):1998;219-223.
19. Leebeek F.W.G., Schipperus M.R., van Vliet H.H.D.M. Coagulation factors in solvent/dergent treated plasma. Transfusion. 39:1999;1150-1151.
20. Zeiler T., Wittmann G., Zimmermann R. et al. The effect of virus inactivation on coagulation factors in therapeutic plasma. Br. J. Haematol. 111:2000;986-987.
21. Matsuda M., Wakabayashi K., Aoki N., Morioka Y. Alpha 2-plasmin inhibitor is among acute phase reactants. Thromb. Res. 17(Suppl):1980;527-532.
22. Hart H., Jones A., Cubie H., McIntosh R.V., Cuthbertson B. Distrubution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate. Vox Sang. 67(Suppl 1):1994;51-55.
23. Wood D.J., Bird C.R., Thorpe R., Barrowcliffe T.W. Hepatitis A virus antibody levels in factor VIII concentrates. Lancet. 344:1994;202-203.
24. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998;317:235-40.